Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 31;41(36):5536–5549. doi: 10.1200/JCO.23.00720

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 4. — Efficacy outcomes in patients with r/mCC treated 2L or 3L with TV + pembrolizumab in the dose-expansion arm F. (A) Waterfall plot showing the maximum percentage change in target lesions. The dashed line indicates a 30% reduction from baseline. (B) Kaplan-Meier–estimated duration of response among the 12 patients with confirmed responses. (C) Kaplan-Meier–estimated overall survival. At data cutoff (June 20, 2022), the median follow-up was 15.0 months (range, 1-29). 2L, second line; 3L, third line; NR, not reached; OS, overall survival; r/mCC, recurrent or metastatic cervical cancer; TV, tisotumab vedotin.